The best protein expression and enzyme activity were found with the iPSC-RPE cells and the codon optimized CYP4V2, thus supporting the development of CYP4V2 gene therapy for BCD treatment (Wang et al., 2022). The gene discussed is CYP4V2; the disease is Bietti crystalline dystrophy.